Redevelopment Following the Return of the License Rights for PPMX-T002 and PPMX-T004
First written in FY2022. 8 of 12 entries say "Advanced", first in FY2023-Q1. Latest entry: 2026-06-03.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「To further enhance the antitumor effect, we changed the RI from 90Y to actinium-225 (225Ac) and verified its efficacy in animal studies. Based on these results, we are seeking to license the program, primarily to radiopharmaceutical developers.」
For PPMX-T002, the RI was changed from 90Y to 225Ac, and efficacy verification in animal studies was completed. Based on these results, the company is seeking to license the program to a radiopharmaceutical developer. - FY2025-H1RestatedAnnual report
「We are currently considering changing the RI from 90Y, primarily to actinium-225 (225Ac), which is expected to offer the highest efficacy, for licensing to a radiopharmaceutical developer, and are refining the development strategy with potential licensees.」
For PPMX-T002, consideration of a development strategy involving a change in the RI, primarily to 225Ac, and licensing to a radiopharmaceutical developer is ongoing. - FY2024AdvancedAnnual report
「We are currently considering changing the RI from 90Y, primarily to actinium-225 (225Ac), which is expected to offer the highest efficacy, for licensing to a radiopharmaceutical developer, and are refining the development strategy with potential licensees.」
For PPMX-T002, the policy of changing the RI from 90Y, primarily to 225Ac, was clarified, and a development strategy with potential licensees is being formulated. A licensing target for the fiscal year ending March 2025 was also indicated. - FY2024-Q2AdvancedAnnual report
「We are currently considering changing the RI from 90Y, primarily to actinium-225 (225Ac), which is expected to offer the highest efficacy, for licensing to a radiopharmaceutical developer, and are refining the development strategy with multiple potential licensees.」
For PPMX-T002, consideration of an RI change was refined into a policy centered on changing from 90Y to actinium-225, and the company advanced to the stage of refining development strategies with multiple potential licensees. - FY2024-Q1RestatedAnnual report
「We are currently refining our development strategy for licensing to a radiopharmaceutical developer, with a change from 90Y to an RI with even greater efficacy under consideration.」
For PPMX-T002, the company is considering a development strategy for licensing to a radiopharmaceutical developer, with a change to a more effective RI under consideration. - FY2023AdvancedAnnual report
「Following discussions with PDR Pharma on future development, it was decided in December 2022 that development and licensing activities would be pursued under our leadership. In an expanded Phase I trial conducted in the United States by a subsidiary of Fujifilm, the licensee, the antibody was confirmed to accumulate in the target cancer cells. We are currently working toward collaboration with a radiopharmaceutical developer, with a change from 90Y to an RI with even greater efficacy under consideration.」
For PPMX-T002, following discussions with PDR Pharma, the policy of advancing development and licensing activities under the company's leadership was clarified, and collaboration with a radiopharmaceutical developer is being pursued, with a change in the RI under consideration. - FY2023-Q3AdvancedAnnual report
「Since March 2022, we had been continuing discussions on future development with PeptiDream Inc. and its subsidiary, PDR Pharma Inc. (hereinafter, PDR Pharma). In December 2022, we entered into a memorandum of understanding with PDR Pharma, and development and licensing activities will be pursued under our leadership. We will work to establish collaboration with a radiopharmaceutical developer, with a change from 90Y to an RI with even greater efficacy under consideration.」
For PPMX-T002, discussions with PDR Pharma progressed to the signing of a memorandum of understanding, clarifying the policy of advancing development and licensing activities under the company's leadership. The company will continue to pursue a change to a more effective RI and collaboration with a radiopharmaceutical developer. - FY2023-Q2RestatedAnnual report
「We are currently continuing discussions on future development with PeptiDream Inc. and its subsidiary, PDR Pharma Inc. We will also pursue collaboration with a radiopharmaceutical developer, with a change in the RI under consideration to further enhance efficacy.」
For PPMX-T002, discussions on development with PeptiDream and PDR Pharma and efforts to pursue collaboration with a radiopharmaceutical developer, with a change in the RI under consideration, are ongoing. - FY2023-Q1AdvancedAnnual report
「PPMX-T002 is a cancer drug candidate consisting of an antibody targeting CDH3, which is highly expressed in cancer cells, labeled with the radioactive isotope yttrium-90 (90Y). Following the return of the license by Fujifilm Corporation, the licensee, we are discussing future development with PDR Pharma Inc., which took over the radiopharmaceutical business of Fujifilm's subsidiary. To further enhance efficacy, we will pursue collaboration with a radiopharmaceutical developer, with a change in the RI under consideration.」
For PPMX-T002, discussions with PDR Pharma regarding future development are underway, and the company has advanced to the stage of pursuing collaboration with a radiopharmaceutical developer, with a change in the RI under consideration. For PPMX-T004, basic studies of the drug and linker have also begun. - FY2022First statedAnnual report
「Both PPMX-T002 and PPMX-T004 are pipeline programs licensed to Fujifilm Corporation, but the licenses were returned in March 2022 following the transfer of its subsidiary's radiopharmaceutical business to another company. PPMX-T002 is a cancer drug candidate labeled with a radioactive isotope (RI). We will select a new collaboration partner and proceed with development, with a change in the RI to enhance efficacy under consideration. PPMX-T004 is an antibody-drug conjugate (ADC) labeled with a drug. It targets the same molecule as PPMX-T002, but will be developed separately from PPMX-T002 without using an RI, with a change in the labeled drug under consideration.」
The policy changed from licensing the programs to Fujifilm to in-house development following the return of the licenses, and a plan was presented for the first time to redevelop PPMX-T002 with a change in the RI and a new collaboration partner, and PPMX-T004 with a change in the labeled drug under consideration.